RxDoctor Payments Data

Ryan Turner, MD

Family Medicine · Blanchard, OKNPI 1780613109

Payments from drug & device makers

$2,146in general payments, 2019–2025

Across 121 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$325
  • AstraZeneca$298
  • Lilly USA, LLC$219
  • Pfizer$210
  • Novo Nordisk$159
  • Amarin Pharma, Inc.$129
  • plus $806 from 20 others

What the payments were for

  • Food & beverage$2,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,146 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$268,193
Medicare patients
446
Services billed
5,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$134,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$82,749
RybelsusSemaglutide37$57,436
JardianceEmpagliflozin51$56,495
MounjaroTirzepatide47$50,073
OzempicSemaglutide50$49,338
TrulicityDulaglutide28$37,032
FarxigaDapagliflozin Propanediol28$28,325
XareltoRivaroxaban12$13,119
LinzessLinaclotide13$13,027
Breo ElliptaFluticasone/Vilanterol18$11,851
Tresiba Flextouch U-100Insulin Degludec16$10,157
Atorvastatin Calcium581$6,652
Fenofibrate49$5,410
Levothyroxine Sodium557$5,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$134,118159 claims
Novo NordiskRybelsus, Ozempic$159$106,77487 claims
GSKTrelegy Ellipta, Breo Ellipta$325$94,600112 claims
Lilly USA, LLCMounjaro, Trulicity$219$87,10675 claims
Boehringer IngelheimJardiance$36$56,49551 claims
AstraZenecaFarxiga, Symbicort$298$31,71544 claims
AbbVieLinzess, Synthroid$125$16,70774 claims
Johnson & JohnsonXarelto$36$13,11912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Blanchard

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →